Axsome Therapeutics said second-quarter 2026 net product revenue rose to $218.4 million, up 46% from $150.0 million a year earlier.
Auvelity drove the largest share of that total, with net product sales of $180.3 million, a 51% increase from $119.6 million in the second quarter of 2025. Sunosi generated $35.8 million in net product revenue, up 20% from $30.0 million a year ago, while Symbravo contributed $2.3 million in sales after launching in June 2025.
Prescription trends also moved higher. About 266,000 total Auvelity prescriptions were written in the quarter, up 34% year over year and 12% from the first quarter. New-to-brand prescriptions for Auvelity rose 26% from the first quarter, and among patients age 65 and older they increased 126% in the first eight weeks after the Alzheimer’s agitation launch compared with the prior quarter’s equivalent period. Sunosi prescriptions reached about 61,000, up 14% from a year earlier and 8% sequentially. Symbravo prescriptions totaled about 23,500, up 30% from the first quarter.
On the expense side, cost of revenue was $13.6 million, little changed from $13.4 million a year ago. Research and development spending fell to $46.2 million from $49.5 million, while selling, general and administrative expenses jumped to $208.1 million from $130.3 million, largely tied to commercialization efforts for Auvelity and Symbravo. The company reported a second-quarter net loss of $51.3 million, compared with a loss of $48.0 million in the same period last year.
Cash and cash equivalents stood at $319.9 million at June 30, 2026, down from $322.9 million at the end of 2025. Shares outstanding were 52,299,889.
Operationally, Axsome launched Auvelity for agitation associated with dementia due to Alzheimer’s disease in June 2026. The company said payer coverage for Auvelity is about 89% of covered lives, including 82% in commercial plans and 100% in government plans. Sunosi coverage is about 82% of covered lives, and Symbravo coverage is about 57%.
In the pipeline, Axsome said the FDA accepted its NDA for AXS-12 in narcolepsy and set a PDUFA date of May 1, 2027. It also initiated the FOCUS-3 and FOCUS-2 phase 3 trials of solriamfetol in adolescents and children with ADHD in June and July 2026. Today the company's shares have moved 2.83% to a price of $218.76. If you want to know more, read the company's complete 8-K report here.
